Physician profile
Frank Parisi
NPI 1326058587
$2,001.54
in general payments reported to CMS, 2019-2025
18 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $75.73 · 2021: $139 · 2022: $307 · 2023: $242 · 2024: $361 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.71 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $472.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $231.73 | 2019-2023 | |
| Abbvie INC. | $202.53 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $195.72 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Biotissue Holdings INC. | $184.58 | 2023-2025 | |
| Alcon Vision LLC | $163.64 | 2022-2025 | Eysuvis, Rocklatan, Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.48 | 2019 | |
| Sun Pharmaceutical Industries INC. | $124.09 | 2019-2025 | |
| Oyster Point Pharma, INC. | $95.43 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $35.33 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $33.31 | 2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $30.00 | 2021-2022 | |
| Sight Sciences, INC. | $19.84 | 2022 | |
| Dompe US, INC. | $19.00 | 2025 | Oxervate |
| Thea Pharma INC. | $16.18 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $15.08 | 2024 | Acthar |
| Harrow Eye, LLC | $14.76 | 2024 | Vevye |
| Shire North American Group INC | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Parisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.